Collagens are the most abundant extracellular matrix (ECM) proteins in the renal stroma. As a result of repetitive or persistent insults, the balance between ECM degradation and formation is disrupted which leads to renal fibrosis. There is a large medical need to find patients at risk as well as identify patients more likely to respond to treatment. The distorted turnover of ECM proteins such as collagens leads to renal fibrosis, which is a strong predictor of progression to end stage renal disease. The Protein FingerprintTM technology allows quantification of protein fragments generated by the ECM turnover directly in serum and/or urine, thereby monitoring the processes of fibrogenesis and fibrolysis.
Many diseases affect kidney function by attacking the glomeruli. As a biopsy is painful and potentially has complications, tools to non-invasively assess the state of the tissue would aid both clinical decisions, but also select patients with an active disease or those that are more likely to respond to treatment. The Protein FingerprintTM technology detects neo-epitopes of relevant extracellular matrix proteins which may allow prognostic enrichment for clinical trials and identification of patients more likely to respond to treatment.
During disease progression, DKD patients present with mesangial expansion and thickening of the glomerular basement membrane, as well as tubulointerstitial fibrosis. It has been shown that the extracellular matrix (ECM) composition in the kidney changes during disease progression. The Protein FingerprintTM technology allows quantification of protein fragments generated during ECM turnover directly in serum and/or urine, thereby monitoring the processes of fibrogenesis and fibrolysis. The biomarkers can aid in separation between healthy and DKD patients and are associated with established disease severity. Protein FingerprintTM biomarkers measured at baseline may be prognostic for adverse outcomes and predict response to treatment. Furthermore, longitudinal assessment of the biomarkers may reveal the impact of a given treatment on ECM remodeling.
The careful evaluation of kidney transplant recipients is important for a successful transplant outcome. With the advances in treatment, most allografts are no longer lost due to acute rejection of the allograft by the kidney transplant recipient, but rather as a result of chronic rejection. There is an urgent need for improved characterization of kidney transplant recipients as neither clinical parameters nor biomarkers are currently available to accurately predict immediate and long-term kidney function after transplantation. Preliminary findings indicate that the PRO-C6 marker has the potential to close that gap.
Please don't hesitate to contact us if you have any questions or other inquiries.